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NK  cells  are  a  fundamental  component  of   
innate immunity against tumors and virally in-
fected cells. The cytolytic activity of NK cells is 
regulated by a dynamic interplay between acti-
vating and inhibitory signals transmitted by dis-
tinct classes of receptors found on their surface 
(Yokoyama and Plougastel, 2003; Bryceson and 
Long, 2008; Lanier, 2008). The dominant signal 
received by an NK cell through its interaction 
with normal numbers of MHC class I molecules 
on target cells is inhibitory. If the number of 
MHC class I molecules is reduced through tu-
morigenic or infectious processes, this inhibitory 
signal is attenuated and the NK cell is activated. 
Inhibitory receptors specific for MHC class I in-
clude the killer immunoglobulin-like receptors 
(KIRs) in humans, members of the Ly49 family in 
rodents, and CD94–NKG2A (Natarajan et al., 
2002; Deng and Mariuzza, 2006).
The discovery of activating NK cell re-
ceptors, including NKG2D, DNAM-1, 2B4, 
and the natural cytotoxicity receptors (NCRs), 
revealed that, in addition to an absent inhibi-
tory signal, activating signals are also required 
for NK cell triggering and tumor cell lysis 
(Moretta et al., 2001; Bryceson and Long, 2008; 
Lanier, 2008). The NCR family includes NKp46 
(NCR1  and  CD335),  NKp44  (NCR2  and 
CD336), and NKp30 (NCR3 and CD337). 
In humans, NKp46 is encoded in the leuko-
cyte receptor complex, whereas NKp44 and 
NKp30 are encoded in the class III region of 
the MHC locus (Moretta et al., 2001). In the 
mouse, only the gene for NKp46 is present, 
with  the  genes  for  the  other  NCRs  being   
absent (NKp44) or a pseudogene (NKp30). 
These very potent activating receptors are type I 
transmembrane glycoproteins comprising one 
(NKp44 and NKp30) or two (NKp46) Ig-like 
extracellular  domains  (Moretta  et  al.,  2001, 
2006). In a manner reminiscent of T, B, and Fc 
receptors, NCRs contain charged residues in 
their transmembrane regions for association 
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Natural killer (NK) cells are lymphocytes of the innate immune system that participate in 
the elimination of tumor cells. In humans, the activating natural cytotoxicity receptors 
(NCRs) NKp30, NKp44, and NKp46 play a major role in NK cell–mediated tumor cell lysis. 
NKp30 recognizes B7-H6, a member of the B7 family which is expressed on tumor, but not 
healthy, cells. To understand the basis for tumor surveillance by NCRs, we determined the 
structure of NKp30, a member of the CD28 family which includes CTLA-4 and PD-1, in 
complex with B7-H6. The overall organization of the NKp30–B7-H6–activating complex 
differs considerably from those of the CTLA-4–B7 and PD-1–PD-L T cell inhibitory com-
plexes. Whereas CTLA-4 and PD-1 use only the front -sheet of their Ig-like domain to 
bind ligands, NKp30 uses both front and back -sheets, resulting in engagement of B7-H6 
via the side, as well as face, of the -sandwich. Moreover, B7-H6 contacts NKp30 through 
the complementarity-determining region (CDR)–like loops of its V-like domain in an  
antibody-like interaction that is not observed for B7 or PD-L. This first structure of an NCR 
bound to ligand provides a template for designing molecules to stimulate NKp30-mediated 
cytolytic activity for tumor immunotherapy.
© 2011 Li et al.  This article is distributed under the terms of an Attribution– 
Noncommercial–Share  Alike–No  Mirror  Sites  license  for  the  first  six  months   
after the publication date (see http://www.rupress.org/terms). After six months it 
is available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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as well as ligands (PD-L1 and PD-L2) for the T cell coin-
hibitory receptor PD-1 (Zou and Chen, 2008). Like all 
known B7 family members, B7-H6 comprises two Ig do-
mains with adjacent phase 1 introns in the extracellular re-
gion.  Importantly,  B7-H6  was  not  detected  in  normal 
human tissues but was selectively expressed on a variety of 
human tumor cell lines, including T and B lymphomas, mel-
anomas, and carcinomas (Brandt et al., 2009). Furthermore, 
B7-H6 expression on tumor cells triggered NKp30-specific 
NK cell cytotoxicity and cytokine secretion. Thus, B7-H6 
functions as a tumor-induced self-molecule that alerts in-
nate immunity to cellular transformation via its interaction 
with the activating receptor NKp30 (Brandt et al., 2009). In 
addition, NKp30 recognizes the tegument pp65 protein of 
human CMV (Arnon et al., 2005), indicating that NKp30 
interacts with multiple ligands, as is the case for the activat-
ing NK receptors NKG2D and DNAM-1 (Raulet, 2003; 
Soriani et al., 2009).
To  date,  crystal  structures  have  been  reported  for 
NKp44 and NKp46 in unbound form (Cantoni et al., 2003; 
Foster et al., 2003) but not for an NCR in complex with a   
with ITAM-bearing signaling polypeptides: DAP12 for NKp44 
and – for NKp46 and NKp30 (Bryceson et al., 2006).
Multiple ligands for NKG2D, DNAM-1, and other acti-
vating NK cell receptors have been identified (Bottino et al., 
2005). In contrast, ligands for the NCR family have been 
elusive, despite the involvement of NCRs in the lysis of 
diverse tumor cell lines and primary tumor cells, including 
neuroblastomas, carcinomas, and lymphoblastic and myeloid 
leukemias (Moretta et al., 2001, 2006). Recently, however, 
NKp30 has been shown to bind the nuclear factor BAT3 
(Pogge von Strandmann et al., 2007) and the tumor cell sur-
face protein B7-H6 (Brandt et al., 2009). BAT3 is involved 
in the induction of apoptosis after DNA damage or endo-
plasmic reticulum stress (Sasaki et al., 2007). As an intracel-
lular protein, BAT3 is not normally expected to be accessible 
to NKp30. However, heat shock resulted in the appearance 
of BAT3 on the surface of tumor cells, making it available to 
bind NKp30 (Pogge von Strandmann et al., 2007). B7-H6 is 
a new member of the B7 family (Brandt et al., 2009), which 
includes ligands (B7-1 and B7-2) for the T cell costimula-
tory receptor CD28 and the coinhibitory receptor CTLA-4, 
Figure 1.  Equilibrium binding of wild-type NKp30 and mutant versions to B7-H6. SPR sensograms for the interaction of wild-type NKp30  
(4.7, 2.4, 1.2, 0.59, 0.29, and 0.15 µM; A), NKp30 F85A/L86A mutant (310, 155, 78, 39, and 19 µM; B), NKp30 I50A/S52A mutant (110, 56, 28, 14, 7.0, and 
3.5 µM; C), and NKp30 S52R mutant (326, 163, 81, 41, and 20 µM; D) with immobilized B7-H6 (200–1000 RU). KDs were calculated from Scatchard plots 
(insets), after correction for nonspecific binding, by measuring the concentration of free reactants and complex at equilibrium. Req is the corrected  
equilibrium response at a given concentration C. KD = 1.0 ± 0.2 × 106 M for wild-type NKp30; 5.3 ± 2.0 × 105 M for F85A/L86A; 1.4 ± 0.3 × 105 M for 
I50A/S52A; 1.5 ± 0.4 ×104 M for S52R. The experiments were independently performed at least twice with similar results.JEM VOL. 208, April 11, 2011 
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NKp30 and B7-H6 individually and then proceed to the 
NKp30–B7-H6 complex.
Structure of NKp30
NKp30 is a type I transmembrane glycoprotein composed of 
a single Ig-like extracellular domain connected by a short 
stalk region of six residues to a transmembrane segment and 
cytoplasmic domain (Pende et al., 1999). NKp30 is mono-
meric in the crystal, in agreement with its behavior as a 
monomer in size exclusion chromatography (unpublished data) 
and on the NK cell surface (Pende et al., 1999). The Ig-like 
domain of NKp30 is a two-layer -sandwich that exhibits the 
chain topology found in IgC domains (C1 set; Williams and 
Barclay, 1988; Fig. 2). The front and back sheets, composed of 
-strands GFC and ABED, respectively, are linked by a ca-
nonical intersheet disulfide bond (Cys39–Cys107). In addi-
tion, NKp30 contains two -helices (1 and 2) preceding 
-strands D and E, respectively. One of these helices (1) is 
unique to NKp30 among Ig-like domains.
A  Dali  structure  homologue  search  (http://www2.ebi 
.ac.uk/dali/fssp/) identified the closest homologue of NKp30 
as the V-like domain of PD-L1, a ligand for the T cell inhibi-
tory receptor PD-1, with a Z-score of 12.8 (24% sequence 
identity). Superposition of NKp30 onto PD-L1 resulted in a 
root mean squared (r.m.s.) difference of 1.8 Å for 101 -carbon 
tumor-derived (or any other) ligand. To obtain atomic-level 
information on MHC-independent tumor surveillance by 
the NCR family, we determined the structures of human 
NKp30 bound to B7-H6 and of B7-H6 in unbound form.
RESULTS
Structure determination
We produced recombinant NKp30 by in vitro folding from 
bacterial inclusion bodies and B7-H6 by secretion from 
baculovirus-infected insect cells. Surface plasmon resonance 
(SPR) was used to demonstrate specific binding of NKp30 
to B7-H6, which is characterized by very fast on and off  
rates (Fig. 1 A). Both rates were too fast to measure reliably. 
Under equilibrium binding conditions, a dissociation con-
stant (KD) of 1.0 ± 0.2 × 106 M was obtained, comparable 
to the affinity of PD-1 for PD-L1 (KD = 6 × 106 M; 
Lázár-Molnár et al., 2008) or of CTLA-4 for B7-1 (4 × 
107 M; van der Merwe et al., 1997). We determined the 
structure of unbound B7-H6 to 2.0 Å resolution by molecular 
replacement using the V-like and C-like domains of human 
PD-L1 (Lin et al., 2008) as separate search models. The par-
tially refined B7-H6 structure and the human CTLA-4 
structure (Schwartz et al., 2001) were used as search models 
for solving the structure of the NKp30–B7-H6 complex to 
2.3 Å resolution (Table I). We first describe the structures of 
Table I.  Data collection and structure refinement statistics
Data collection NKp30–B7-H6 B7-H6
Space group P212121 P21
Unit cells (Å, o) a = 50.9, b = 74.9, c = 125.5 a = 44.3, b = 70.6, c = 53.2,  = 100.4°
Resolution (Å)a 50–2.3 (2.38–2.30) 50–2.0 (2.07–2.00)
Observations 299,606 159,065
Unique reflections 21,751 21,805
Completeness (%)a 98.4 (88.2) 100 (99.6)
Mean I/(I)a 53.4 (3.3) 58.0 (2.6)
Rsym (%)a,b 6.5 (48.5) 5.7 (47.6)
Refinement
Resolution range (Å) 50–2.30 50–2.0
Rwork (%)c 23.9 24.2
Rfree (%)c 28.9 28.9
Protein atoms 2,543 1,665
Carbohydrate atoms 56 70
Water molecules 16 32
r.m.s. deviations from ideality
Bond lengths (Å) 0.019 0.019
Bond angles (°) 1.99 1.88
Ramachandran statistics (%)
Favorable 85.5 93.3
Additional 12.7 5.6
Generous 1.4 1.1
Forbidden 0.4 0.0
aValues in parentheses are statistics for the highest resolution shells.
bRsym = ∑|Ij  <I>|/∑Ij, where Ij is the intensity of an individual reflection and <I> is the average intensity of that reflection.
cRwork = ∑||Fo|  |Fc||/∑|Fo|, where Fc is the calculated structure factor. Rfree is as for Rwork but calculated for a randomly selected 5.0% of reflections not included in the refinement.706 Structure of NKp30 bound to B7-H6 | Li et al.
domain and a membrane proximal C-like domain (Fig. 2). 
B7-H6 behaved as a monomer in solution (unpublished data) 
and  crystallized  as  a  monomer  in  both  free  and  NKp30-
bound forms. B7-H6 and PD-L1 share significant structural 
similarity, with a Z-score of 16.9 (20% sequence identity) and 
r.m.s. difference of 2.8 Å (191 -carbon atoms). The struc-
tural similarity between NKp30 and B7-1 is lower but still 
notable (Z-score = 14.1; 17% sequence identity; r.m.s. differ-
ence = 5.3 Å for 177 -carbon atoms). The two antiparallel 
-sheets of the B7-H6 V-like domain are formed by strands 
GFCCC and ABE, whereas the -sandwich of the C-like 
domain is composed of strands GFCC and ABED. B7-H6 
contains six potential N-linked glycosylation sites, two in the 
V-like and four in the C-like domain. In both the free and 
NKp30-bound B7-H6 structures, clear electron density was 
visible for carbohydrate chains attached to Asn43 and Asn57 
in the V-like domain and to Asn208 in the C-like domain 
(Fig. S1). The V-like domain of B7-H6 terminates at Val140, 
which is followed by a three-residue coil (Ala141Ser142Pro143) 
before the start of -strand A of the C-like domain (Fig. S2). 
However, this coil is integral to the C-like domain rather than 
forming a flexible interdomain linker, as in antibody mole-
cules, which probably helps stabilize the extended, upright 
stature of B7-H6.
A  structure-based  sequence  alignment  of  B7-H6  and 
NKp30 showed several shared secondary structural elements, 
notably strands ABCEFG and helix 2, which is unique to 
these two proteins among Ig-like domains (Fig. 3, C and D). 
Additionally, superposition of B7-H6 onto NKp30 resulted 
in an r.m.s. difference of 1.7 Å for 81 -carbon atoms, indi-
cating close similarity. The main differences between these 
molecules reside on one side of the -sandwich, where B7-H6 
has strands CC and NKp30 instead has strand D, helix 1, 
and a long loop connecting strand C and helix 1.
Overview of the NKp30–B7-H6 complex
The structure of the NKp30–B7-H6 complex revealed an   
assembly with a 1:1 receptor–ligand stoichiometry and a 
binding interface formed by the front and back -sheets of 
the NKp30 C-like domain and the front -sheet of the B7-H6 
V-like domain (Fig. 2). Residues from strands CF and loops 
BC and FG (front sheet) of NKp30, along with helix 2 
(back  sheet),  juxtapose  residues  from  strands  GFCC  and 
loops BC, CC, and FG (front sheet) of B7-H6. The overall 
organization of the NKp30–B7-H6 complex differs consid-
erably from those observed in the PD-1–PDL1 (or PD1–
PDL2;  Lázár-Molnár  et  al.,  2008;  Lin  et  al.,  2008)  and 
CTLA-4–B7-1 (or CTLA-4–B7-2) structures (Schwartz et al., 
2001; Stamper et al., 2001). These differences are best appreci-
ated by superposing NKp30 in the NKp30–B7-H6 complex 
onto PD-1 and CTLA-4 in the PD-1–PD-L and CTLA-4–B7 
complexes (Fig. 4, A and B). Compared with NKp30, PD-1 
and CTLA-4 engage their ligands at angles of 90° and 
60°, respectively.
The difference in overall complex architecture is ex-
plained by two main differences in the binding mode of 
atoms. The structural similarity between NKp30 and PD-1 is 
lower (Z-score = 10.8; 21% sequence identity; r.m.s. differ-
ence = 3.1 Å for 101 -carbon atoms), indicating that NKp30 
is more structurally akin to the PD-L1 ligand than to its re-
ceptor. NKp30 is considered a member of the CD28 family, 
which includes PD-1 (CD279), CTLA-4 (CD152), ICOS 
(CD278), and BTLA (CD272; Brandt et al., 2009). Superpo-
sition of NKp30 onto CTLA-4 (Z-score = 10.1; 28% sequence 
identity) gave an r.m.s. difference of 2.6 Å (95 -carbon 
atoms). Thus, NKp30 is clearly more structurally related to 
PD-1 and CTLA-4 than to adhesion molecules, such as CD2 
(Z-score = 9.2 for domain 1; 16% sequence identity) and 
CD58 (9.2 for domain 1; 16%; Wang et al., 1999), or to the 
NCRs NKp44 (9.1; 14%; Cantoni et al., 2003) and NKp46 
(8.6 for domain 1; 15%; Foster et al., 2003).
Although -strands GFC in the front sheet and ABE in 
the back sheet of NKp30 align well with the corresponding 
strands of PD-1 and CTLA-4, there are large differences on 
one side of the -sandwich. Whereas the back sheets of PD-1 
and CTLA-4 also include strands CC or C, NKp30 lacks 
these strands and instead contains helices 1 and 2 connected 
by a short D strand (Fig. 3, A and B). One of these helices (2) 
participates in binding B7-H6, as discussed in the next section.
Structure of B7-H6
Like other members of the B7 family, the extracellular por-
tion  of  B7-H6  is  composed  of  a  membrane  distal V-like   
Figure 2.  Two views of the NKp30–B7-H6 complex. The strands of 
the two -sheets of NKp30 are labeled GFC and ABED. The strands of the 
two -sheets of the V-like domain of B7-H6 are labeled GFCCC and 
ABE; those of the C-like domain are labeled GFCC and ABED. N-linked 
glycans at B7-H6 residues Asn43 and Asn57 in the V-like domain and 
Asn208 in the C-like domain are shown in ball-and-stick representation. 
The view at right is after a rotation of 45° around the vertical axis. The  
C termini are identified.JEM VOL. 208, April 11, 2011 
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The NKp30–B7-H6 interface
In the complex, 12 NKp30 residues contact 11 B7-H6 resi-
dues through predominantly hydrophobic interactions, with no 
bound water molecules in the interface (Fig. 5 A; Table II). 
The three potential N-linked glycosylation sites of NKp30 
are located outside the interface with B7-H6 and so should 
not  interfere  with  binding. The  NKp30–B7-H6  complex 
buries a total solvent-accessible surface of only 1,130 Å2, of 
which 578 Å2 is contributed by NKp30 and 552 Å2 by B7-H6. 
This small interface, which is similar in size to that of the 
CTLA-4–B7-1 complex (1,250 Å2) but substantially less than 
the interface of the PD-1–PDL1 complex (1,900 Å2), is at the 
lower limit of the mean value of 1,600 (±400) Å2 for stable 
protein–protein complexes (Lo Conte et al., 1999). However, 
the interface is characterized by high shape complementarity, 
based on a calculated shape correlation statistic (Sc; Lawrence 
and Colman, 1993) of 0.77 (Sc = 1.0 for interfaces with geo-
metrically perfect fits), which is at the upper end of the range 
for protein–protein complexes. This high Sc value is readily 
NKp30. First, whereas PD-1 and CTLA-4 use only their 
front -sheets to engage the corresponding -sheets of their 
ligands in a face-to-face manner (Fig. 4, D and E), the binding 
site of NKp30 comprises elements from both its front and 
back -sheets, resulting in engagement of B7-H6 via the side, 
as well as face, of the NKp30 -sandwich (Fig. 4 C). Second, 
B7-H6 contacts NKp30 in an antibody-like manner (see 
the next section), with greater involvement by the loops of 
the V-like domain of the ligand than is the case for PD-L 
or  B7. In  the  PD-1–PD-L  complex,  whose  interface  is 
dominated by strand-to-strand interactions (Fig. 4 D), the re-
sult is a relatively compact structure with an end-to-end dis-
tance  spanning  75 Å,  compared  with  100 Å  for  the 
NKp30–B7-H6 complex (Fig. 4 A). However, in the CTLA-
4–B7 complex, the involvement by the loops of CTLA-4 in 
binding ligand, which is greater than in the case of NKp30 
(Fig. 4, C and E), results in as extended a structure as the 
NKp30–B7-H6 complex, with a similar end-to-end distance 
of 100 Å (Fig. 4 B).
Figure 3.  Comparison of NKp30 with PD-1, CTLA-4, and B7-H6. (A) Superposition of the C-like domain of NKp30 (green) onto the V-like domain 
of PD-1 (magenta; Protein Data Bank accession code 3BIK). (B) Superposition of the C-like domain of NKp30 (green) onto the V-like domain of CTLA-4 
(blue; 1IL8). (C) Superposition of the C-like domain of NKp30 (green) onto the V-like domain of B7-H6 (yellow). (D) Structure-based sequence alignment 
of NKp30 and B7-H6 Ig-like domains. Secondary structure elements are denoted by squiggles (-helices) and arrows (-strands). Contacting residues in 
the NKp30–B7-H6 complex are marked with black dots. White characters on a red background show strictly conserved residues. Residues that are well 
conserved are drawn in red and framed in blue. The remaining residues are black. Sequence alignments were performed with the program ClustalW 
(http://www.expasy.ch).708 Structure of NKp30 bound to B7-H6 | Li et al.
Figure 4.  Comparison of the NKp30–B7-H6, PD-1–PD-L1, and CTLA-4–B7-1 complexes. (A) Overlay of the NKp30–B7-H6 and PD-1–PD-L1 
complexes by superposing NKp30 (green) onto PD-1 (magenta). B7-H6 is yellow; PD-L1 is orange. (B) Overlay of the NKp30–B7-H6 and CTLA-4–B7-1 
complexes by superposing NKp30 (green) onto CTLA-4 (blue). B7-H6 is yellow; B7-1 is red. (C–E) Docking modes in the NKp30–B7-H6, PD-1–PD-L1, and 
CTLA-4–B7-1 complexes. The three complexes were overlaid by superposing the V-like domains of B7-H6 (yellow), PD1-L1 (orange), and B7-1 (red), and 
then translated horizontally for viewing.
Table II.  Interactions between NKp30 and B7-H6
B7-H6 NKp30
Hydrogen bondsa and salt bridgeb Distance (Å)c Van der Waals contacts
Thr59 Ile50
Ser60 Ile50, Leu86
Met61 Ile50
Gly62 Leu113
Phe82 Leu113, Gly114
Gly83 Ile50
Val125 Ile50, Glu111, Leu113
Thr127 Thr127 O–Gly51 Na 3.33 Ile50, Gly51, Ser82, Phe85, Leu86
Pro128 Pro128 O–Val53 Na 3.37 Gly51, Ser52, Val53, Leu80, Ser82, Phe85
Leu129 Ser52
Lys130 Lys130 N–Glu111 O1b 3.09 Ser52, Glu111
aHydrogen bond.
bSalt bridge.
cDistance indicates length of hydrogen bond or salt bridge.JEM VOL. 208, April 11, 2011 
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The only two hydrogen bonds in the interface are formed by 
these two FG loop residues: B7-H6 Thr127 O–N NKp30 
Gly51 and B7-H6 Pro128 O–N NKp30 Val53 (Fig. 5 A; 
Table II). Notably, the FG loop corresponds to complementarity- 
determining region (CDR) 3 of antibodies and T cell recep-
tors. Additional contacts are provided by residues from the BC 
(CDR1-like) and CC (CDR2-like) loops of B7-H6, under-
scoring an antibody-like interaction with NKp30 which is 
not evident in the interaction of PD-L or B7 with their re-
ceptors (Fig. 4, C–E). In particular, B7-H6 Thr59 and Ser60 
(BC  loop)  engage  NKp30  Ile50  (BC  loop)  and  Leu86   
(2 helix) through multiple main chain–main contacts (Fig. 5 A). 
Overall, the CDR-like loops of B7-H6 contribute 64% of the 
total contacts to the receptor, compared with 13 and 18%   
explained by the topologies of the contacting surfaces, whereby 
the FG loop of B7-H6 forms a prominent bulge on the sur-
face of the ligand which fits snugly into a deep groove be-
tween strands FG and helix 2 of the NKp30 receptor that is 
unique to this CD28 family receptor (Fig. 5 B). The high 
shape complementarity of the NKp30–B7-H6 interface, which 
is also characterized by the complete exclusion of bulk sol-
vent, probably compensates for its small size to achieve suffi-
cient affinity for NK cell activation.
Residues Thr127 and Pro128 of the FG loop of B7-H6 
each make 16 van der Waals contacts with NKp30, which 
together account for nearly half (44%) the total number of 
contacts (73) in the complex. These residues bind at the base of 
groove between strands FG and helix 2 of NKp30 (Fig. 5 B). 
Figure 5.  The NKp30–B7-H6 binding interface. (A) Stereo view of the NKp30–B7-H6 interface. The side chains of interacting residues are shown in 
ball-and-stick representation, with carbon atoms in cyan (NKp30) or orange (B7-H6), nitrogen atoms in blue, and oxygen atoms in red. Hydrogen bonds 
are drawn as dotted black lines. A salt bridge linking residues NKp30 Glu111 and B7-H6 Lys130 is shown as a solid black line. (B) The NKp30 molecular 
surface is shown in gray with the region contacting B7-H6 colored green. Residues 125–130 of the B7-H6 FG loop are drawn in stick format and labeled.710 Structure of NKp30 bound to B7-H6 | Li et al.
Gly83 is shifted by 2.7 Å toward the receptor to allow formation 
of van der Waals contacts with NKp30 Ile50 and Leu113. 
The main chains of loops BC and FG of B7-H6 are each dis-
placed 1.6 Å away from NKp30 to avoid steric clashes with 
the receptor.
In addition to structural adjustments in regions of B7-H6 
that contact NKp30, helix 2 of B7-H6 is displaced toward 
the body of the ligand by a mean of 1.7 Å in the position of 
its -carbon atoms (Fig. 6 A). This helix is located on the back 
sheet of the B7-H6 -sandwich and opposite the receptor bind-
ing site. However, this movement does not appear to be attrib-
utable to NKp30 binding but rather to lattice contacts with a 
neighboring NKp30 molecule in the crystal. Free and bound 
B7-H6 exhibit nearly identical hinge angles between the V-like 
and C-like domains, suggesting limited conformational flexi-
bility in the interdomain region that is unrelated to receptor 
binding. In contrast, the hinge angles of free and bound PD-L1 
were found to differ by 40° (Lin et al., 2008), indicating sub-
stantially greater flexibility that is likely attributable to structural 
differences in the interdomain regions of PD-L1 and B7-H6.
DISCUSSION
The NKp30–B7-H6 structure revealed that this NK cell acti-
vating complex is distinct from the CTLA4–B7 and PD-1–
PD-L T cell inhibitory complexes in both overall organization 
and detailed atomic interactions that mediate binding and 
specificity. The structure provides the first information on the 
molecular basis for tumor cell recognition by any member of 
the NCR family, which includes NKp30, NKp44, and NKp46. 
In addition, the NKp30–B7-H6 structure establishes certain 
constraints that must be satisfied by any mechanism proposed 
to describe signaling through the NKp30 
pathway and the integration of these sig-
nals into the overall NK cell response.
Upon NK cell–target cell interaction,   
a highly organized complex of molecules, 
termed the NK cell immune synapse, is 
formed at the contact area of both cells 
(Orange, 2008). These molecules include 
inhibitory NK receptors that monitor MHC 
class I expression on target cells (KIRs and 
Ly49s in human and mouse, respectively), 
activating  NK  receptors  that  recognize 
MHC-like or non-MHC ligands (NKG2D, 
DNAM-1, and 2B4), cytoskeletal proteins 
for CDR-like loops of PD-L1 and B7-1, respectively. The 
remaining interactions are contributed by strands C, F, and G, 
including a salt bridge linking B7-H6 Lys130 (G stand) with 
NKp30 Glu111 (Fig. 5 A; Table II). On the NKp30 side of the 
interface, the CDR-like loops of the receptor account for 
46% of the total contacts to B7-H6, with helix 2 making a 
substantial contribution (16%).
To functionally validate the NKp30–B7-H6 interface ob-
served in the crystal structure, we mutated contacting residues 
of NKp30 in loop BC (Ile50), -strand C (Ser52), or helix 2 
(Phe85, Leu86) and measured binding to B7-H6 by SPR. 
Mutation of NKp30 Phe85 and Leu86 to alanine reduced 
affinity for B7-H6 by 53-fold (KD = 5.3 × 105 M versus 
1.0 × 106 M for wild-type NKp30; Fig. 1 B). A less pro-
nounced (14-fold), though still significant, effect resulted from 
alanine substitution of NKp30 Ile50 and Ser52 (Fig. 1 C). 
Much more disruptive was the replacement of NKp30 Ser52 
by arginine (Fig. 1 D), which reduced binding to B7-H6 
by 150-fold, thereby confirming the interface identified in 
the structure.
Conformational changes in B7-H6 upon binding NKp30
Superposition of the V-like domain of free B7-H6 onto the 
V-like domain of B7-H6 in the complex with NKp30 gave 
an r.m.s. difference in -carbon positions of 1.1 Å, indicating 
close overall similarity (Fig. 6 A). However, strands CC and 
their associated CC loop have undergone a movement   
toward NKp30 to optimize interactions with the receptor 
(Fig. 6 B). In loop CC, the side chain of B7-H6 Phe82 is 
rotated by 90° around the C–C axis to avoid steric clashes 
with  NKp30  Leu113,  and  the  -carbon  atom  of  B7-H6 
Figure 6.  Conformational changes in B7-H6 
upon binding NKp30. (A) Comparison of free B7-H6 
(violet) and B7-H6 (yellow) in complex with NKp30. 
The two structures were superposed through the  
V-like domain of B7-H6. The NKp30 molecule bound 
to B7-H6 is green; a neighboring NKp30 molecule in 
the crystal is cyan. (B) Structural rearrangements in 
B7-H6 induced by binding to NKp30. Bound B7-H6 is 
yellow; unbound B7-H6 is violet.JEM VOL. 208, April 11, 2011 
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for CTLA-4, forms noncovalent dimers (Ikemizu et al., 2000), 
B7-H6 is monomeric both in solution and the crystal. The 
monomeric state of NKp30 and B7-H6 precludes formation 
of the type of alternating, periodic assembly observed in 
CTLA-4–B7 crystal structures, in which bivalent CTLA-4 
homodimers bridge bivalent B7 homodimers in the immune 
synapse (Schwartz et al., 2001; Stamper et al., 2001). Instead, 
simple diffuse processes probably mediate the engagement 
NKp30 and B7-H6 in interacting cells and the subsequent 
accumulation of NKp30–B7-H6 complexes in the central zone 
of the immune synapse, as proposed for PD-1–PD-L complexes, 
which are also monomeric (Lázár-Molnár et al., 2008).
Although NKp30 is structurally unrelated to NKG2D, 
which belongs to the C-type lectin-like superfamily, these 
two activating NK receptors present several intriguing paral-
lels. Both recognize induced self-molecules expressed on   
tumor cells that alert innate immunity to cellular transforma-
tion:  MICA  and  MICB  for  NKG2D  (Raulet,  2003)  and   
B7-H6 for NKp30 (Brandt et al., 2009). Moreover, both recep-
tors bind multiple ligands. Besides MICA and MICB, human 
NKG2D interacts with ULBP1–4, whereas mouse NKG2D 
binds H-6, RAE-1, and MULT1 (Raulet, 2003). Likewise, in 
addition  to  B7-H6,  NKp30  recognizes  the  nuclear  factor 
BAT3 (Pogge von Strandmann et al., 2007) and pp65, a human 
CMV  tegument  protein  (Arnon  et  al.,  2005).  However, 
whereas all NKG2D ligands are structurally related to MHC 
class I molecules, B7-H6, BAT3, and pp65 appear to be com-
pletely unrelated, both in terms of their structure (the proteins 
lack any sequence homology) and origin (B7-H6 is a cell 
(F-actin and tailin), and integrins (CD11a and CD11b; Vyas 
et al., 2002; Orange, 2008). It has been proposed that the unique 
compartmentalization of molecules observed at immune syn-
apses is regulated by a sorting mechanism based on molecular 
dimensions, with relatively small signaling molecules (e.g., 
NK receptors) localizing to a central zone and larger adhesion 
molecules (e.g., integrins) residing in the periphery (van der 
Merwe et al., 2000; Bromley et al., 2001; Orange, 2008). 
Accordingly, we compared the dimensions of the NKp30–
B7-H6 complex with those of the KIR–MHC and NKG2D–
MICA complexes (Boyington et al., 2000; Li et al., 2001), 
both of which accumulate at the NK cell synapse (Davis et al., 
1999; McCann et al., 2007; Orange, 2008; Fig. 7). In the 
NKp30–B7-H6 complex, the distance spanned by the mole-
cules is 100 Å, which is approximately the distances bridged 
by the KIR–HLA-C and NKG2D–MICA complexes. This 
suggests that these receptor–ligand pairs could potentially co-
localize with NKp30–B7-H6 in the central zone of the 
NK cell immune synapse. In addition, tumor cells expressing 
both MICA and B7-H6 could possibly trigger synergistic 
activation of NK cells.
An important feature of NKp30 and B7-H6 is their mono-
meric nature. Whereas CTLA-4 exists as a disulfide-linked 
homodimer on the T cell surface, NKp30, like PD-1, exists as 
a monomer in solution, in the crystal, and on the NK cell 
surface (Pende et al., 1999). In this regard, it should be noted 
that NKp30 and PD-1 lack the extracellular equivalent of 
Cys122 in CTLA-4 that forms the intermolecular disulfide in 
the CTLA-4 homodimer. Similarly, whereas B7, the ligand 
Figure 7.  Hypothetical model of interactions at the human NK cell–target cell immune synapse. The distance spanned by the NKp30–B7-H6 
complex is comparable to those spanned by the KIR2DL2–HLA-Cw3 (1EFX) and NKG2D–MICA (1HYR) complexes.712 Structure of NKp30 bound to B7-H6 | Li et al.
Ni2+-NTA column (GE Healthcare) for affinity purification. Recombi-
nant  B7-H6  was  further  purified  by  sequential  Superdex  S-75  and 
MonoQ columns.
Crystallization  and  data  collection.  Crystals  of  unbound  B7-H6   
(10 mg/ml) were grown in hanging drops at room temperature in 0.2 M 
LiCl2 and 20% (wt/vol) polyethylene glycol (PEG) 3350. For crystallization 
of the NKp30–B7-H6 complex, 5 mg/ml NKp30 and 10 mg/ml B7-H6 
were mixed in a 1:1 volume ratio. The complex crystallized in 20% (wt/vol) 
PEG 3350 and 0.2 M KF in hanging drops at room temperature.
For data collection, both crystals were transferred to a cryoprotectant 
solution of mother liquor containing 30% (vol/vol) glycerol, before flash 
cooling in liquid nitrogen. X-ray diffraction data were collected to 2.0 Å 
resolution for unbound B7-H6 and to 2.3 Å resolution for the NKp30–
B7-H6 complex at beamline X29 of the Brookhaven National Synchro-
tron Light Source. The B7-H6 crystal belongs to space group P21 with 
one molecule per asymmetric unit; the NKp30–B7-H6 crystal belongs to 
space group P212121 with one complex molecule per asymmetric unit. All 
data were indexed, integrated, and scaled with the program HKL2000 
(Otwinowski and Minor, 1997). Data collection statistics are summarized 
in Table I.
Structure determination and refinement. The structure of B7-H6 was 
solved by molecular replacement with Phaser (Storoni et al., 2004) using the 
V-like and C-like domains of human PD-L1 (Protein Data Bank accession 
no. 3BIK; Lin et al., 2008) as separate search models. The partially refined 
B7-H6 structure and the human CTLA-4 structure (1I85; Schwartz et al., 
2001) were used as search models for solving the structure of the NKp30–
B7-H6 complex. All refinements were performed using the program CNS1.1 
(Brünger et al., 1998), including iterative cycles of simulated annealing, posi-
tional refinement, and B factor refinement, interspersed with model rebuild-
ing into A-weighted Fo  Fc and 2Fo  Fc electron density maps using 
XtalView (McRee, 1999). Refinement statistics are summarized in Table I. 
Stereochemical parameters were evaluated with PROCHECK (Laskowski   
et al., 1993). Atomic coordinates and structure factors for the NKp30–B7-H6 
complex and B7-H6 have been deposited in the Protein Data Bank under 
accession nos. 3PV6 and 3PV7, respectively.
SPR analysis. The interaction of wild-type and mutant NKp30 receptors 
with  B7-H6  was  assessed  by  SPR  using  a  BIAcore T100  biosensor   
(GE Healthcare). Typically, 200–1,000 resonance units of B7-H6 were immobi-
lized on a CM5 sensor chip by random amine-coupling. Solutions contain-
ing different concentrations of NKp30 were injected sequentially over flow 
cells immobilized with B7-H6 or buffer as a blank. The data were analyzed 
using BIAevaluation 4.1 software (GE Healthcare). Dissociation constants 
(KDs) were determined from Scatchard analysis, after correction for nonspe-
cific binding, by measuring the concentration of free reactants and complex 
at equilibrium. Standard deviations for two or more independent KD deter-
minations were typically <20%.
Online supplemental material. Fig. S1 shows electron density for two 
N-acetylglucosamine residues linked to Asn208 of B7-H6 in the NKp30–
B7-H6 complex. Fig. S2 shows the interdomain region of B7-H6. Online 
supplemental material is available at http://www.jem.org/cgi/content/ 
full/jem.20102548/DC1.
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surface protein; BAT3 is a nuclear protein released upon heat 
shock; pp65 is a structural protein of CMV found in the 
nucleus and cytoplasm of infected cells). In the case of NKG2D, 
crystallographic studies of NKG2D bound to MICA, ULBP3, 
and RAE-1 (Li et al., 2001, 2002; Radaev et al., 2001;   
McFarland et al., 2003) have shown that NKG2D recognizes 
these MHC-like ligands using a single binding site formed by 
the two identical subunits of this homodimeric receptor. In ad-
dition, only 60% of the solvent-accessible surface in the 
NKG2D–ligand complexes is nonpolar (McFarland et al., 2003), 
whereas the NKp30–B7-H6 interface is 69% hydrophobic. 
Whether NKp30 binds BAT3 and pp65 through the same 
site as B7-H6 is not clear, given the disparate nature of these 
ligands. It is conceivable that NKp30 may possess distinct, al-
beit overlapping, binding sites for these molecules, which may 
comprise residues from both its front and back -sheets, as 
seen in the NKp30–B7-H6 complex, or be restricted to residues 
from the front -sheet alone, in the manner of the CTLA4–B7 
and PD-1–PD-L complexes (Schwartz et al., 2001; Stamper 
et al., 2001; Lázár-Molnár et al., 2008; Lin et al., 2008).
The availability of the NKp30–B7-H6 structure should 
accelerate the development of molecules to manipulate the 
NKp30  pathway  for  tumor  immunotherapy.  For  example, 
soluble forms of B7-H6, or compounds designed to mimic 
the CDR-like loops of B7-H6 that bind NKp30, could be 
used to augment NK cell responses to tumor cells through 
induction of NKp30-mediated cytolytic activity. Alternatively, 
soluble forms of NKp30 fused to antibody Fc regions with 
effector  functions  may  serve  as  reagents  for  eliminating 
B7-H6–expressing tumor cells via antibody-dependent cell- 
mediated cytotoxicity. Although such therapeutic applications 
will likely require structure-based engineering of variants of 
NKp30 that bind B7-H6 with high affinity (or vice versa), 
this has been achieved in the case of belatacept (Larsen et al., 
2005), a high-affinity mutant of CTLA-4 in clinical trials for 
preventing rejection in kidney transplantation (Snanoudj 
et al., 2007).
MATERIALS AND METHODS
Protein  production  and  purification. The  extracellular  portion  of 
NKp30  (residues  Leu19–Gly135)  was  cloned  into  the  expression  vector 
pET-26b (Novagen) and expressed as inclusion bodies in BL21(DE3) Esche-
richia coli cells (EMD). The inclusion bodies were washed with 50 mM Tris-
HCl, pH 8.0, containing 5% (vol/vol) Triton X-100, and then dissolved in   
8 M urea, 50 mM Tris-HCl, pH 8.0, and 10 mM DTT. For in vitro folding, 
the inclusion bodies were diluted into ice-cold folding buffer containing   
0.4 M l-arginine–HCl, 50 mM Tris-HCl, pH 8.0, 1 mM EDTA, 3 mM re-
duced glutathione, and 0.9 mM oxidized glutathione to a final protein con-
centration of 40 mg/liter. After 72 h at 4°C, folded proteins were separated 
from aggregates using a Superdex S-75 column (GE Healthcare). Further 
purification was performed by MonoS chromatography. Mutants of NKp30 
were constructed by overlap PCR and expressed in E. coli in the same way as 
the wild-type receptor.
The  extracellular  portion  of  B7-H6  (residues Asp25–Ser262)  was 
fused to the gp67 secretion signal sequence of baculovirus expression vec-
tor pAcGP67-B (BD) with a C-terminal His6 tag and expressed in SF9 
insect cells (Invitrogen). In a typical preparation, 500 ml Sf9 cells at 1.4 × 106 
cells/ml were inoculated with 12 ml of recombinant baculovirus at 1.0 × 108 
pfu/cell. Supernatants were harvested 4 d after infection and loaded onto a JEM VOL. 208, April 11, 2011 
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